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1. Introduction
Schizophrenia is a chronic debilitating mental illness, 
which is characterized by thought, affective, and behavioral 
abnormalities and progresses with cognitive dysfunctions. 
Heterogeneity in clinical symptoms and the nature of 
neurocognitive dysfunction in schizophrenia suggests that 
several brain regions are involved in the pathophysiology 
of the disorder. Abnormalities in the prefrontal cortex 
(PFC), which is responsible for cognitive functions such 
as working memory, executive functions, and attention; 
the anterior cingulate cortex (ACC), which is responsible 
for integration of emotions and behaviors; the thalamus, 
which is responsible for interactions of cognitive and 
sensorial inputs in cortical areas; and hippocampal 
dysfunction and memory impairment are all known to 
have important roles in the etiology of schizophrenia (1). 
Magnetic resonance spectroscopy (MRS) is an 
imaging technique that provides information about 
the neurochemical structure of the brain. The PFC and 
hippocampus are the most commonly investigated areas 
in schizophrenia by using MRS. The most commonly 
studied molecules are N-acetylaspartate (NAA), which is 
an important amino acid indicating the viability/integrity 
of neurons; choline (Cho), which provides information 
about cell membrane turn-over; creatinine (Cre), having 
a role in cellular energy metabolism; and myoinositol 
(myo-I), which is accepted as the marker for glial cells 
(2,3). Although it was reported that NAA decreases in the 
prefrontal lobe and medial temporal region including the 
hippocampus were a consistent finding in schizophrenia 
patients (4), no change in NAA levels could be found in 
the dorsolateral prefrontal cortex (DLPFC) of subjects 
with high genetic risk of schizophrenia (5), medicated 
patients with chronic deficit-syndrome schizophrenia 
(6), and medicated chronic patients (7) as compared to 
controls. However, several studies reported decreased PFC 
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NAA levels in medicated chronic schizophrenia patients 
(CSPs) (8,9), first episode patients (FEPs) (7,10,11), and 
medicated schizophreniform spectrum patients (12). 
Similarly, several studies reported decreased hippocampal 
NAA levels (4), and a few studies reported unaltered NAA 
levels in chronic patients (13,14) and in medicated and 
unmedicated FEPs (15–17). Contrasting the above results, 
FEPs and drug-naive schizophrenia patients showed 
decreased hippocampal NAA/Cre ratios compared to 
medicated FEP (18).
 The other most commonly investigated anatomic area 
in schizophrenia by using MRS is the anterior cingulate 
cortex (ACC), which is known to have strong reciprocal 
connections with limbic structures and to be an important 
contributor of the frontal cortex system (19). Several 
studies reported that there are statistically significant 
differences in metabolite levels in the ACC between 
CSPs and healthy controls (20–22). Lower NAA levels in 
schizophrenia patients receiving typical antipsychotics 
were reported when compared with the ones receiving 
atypical antipsychotics (23), and no difference in NAA 
levels was also reported in schizophrenia patients 
receiving atypical antipsychotics when compared with 
control subjects (24). When the literature is reviewed, 
studies about Cho, Cre, and myo-I metabolites in the 
ACC are limited. Many studies have supported that these 
metabolites do not differ in schizophrenia patients when 
compared with healthy controls (21,25,26).
In some studies that compared FEPs with CSPs, the 
PFC NAA/Cre levels were determined to be lower in CSPs 
when compared with healthy controls and FEPs (7,8,27). 
Başoğlu et al. compared 15 CSPs with 13 FEPs, and they 
reported that there were lower NAA/Cre ratios in CSPs and 
FEPs in the temporal cortex and thalamus when compared 
with healthy controls (28). Szulc et al. compared 31 FEPs 
with 17 CSPs and 13 healthy controls, and they reported 
that there was no significant difference in brain metabolite 
levels between the patient groups. They also reported that 
there was an increasing tendency in Cho levels in the 
temporal lobe in CSPs, a decreasing tendency in NAA 
levels in FEPs, and a statistically significant increase in 
Cho levels in the frontal lobe in both patient groups when 
compared with the controls (29). Along with differences 
between brain imaging techniques, there are limitations 
as some studies investigating FEPs and CSPs were focused 
on single brain areas such as the DLPFC, thalamus, or 
medial temporal cortex (8,9,29), and some of first episode 
studies included patients with psychotic disorders other 
than schizophrenia. Therefore, it is still unclear whether 
there are differences in neuronal integrity between FEPs 
and CSPs and which areas are related with the differences 
(15,18). Moreover, results regarding metabolites other than 
NAA are also inconclusive. While it was reported that Cho 
levels were decreased in the frontal cortex in some studies, 
they were reported to be increased in other studies, and 
there are few data related to myo-I levels indicating glial 
pathology (27,30,31).
In the present study, it was aimed to compare 
neurometabolite (NAA, Cho, Cre, and myo-I) levels in 
the areas playing a role in schizophrenia etiology such as 
the DLPFC, thalamus, hippocampus, and ACC in CSPs 
and FEPs who were clinically followed and confirmed 
diagnostically for schizophrenia with healthy controls. We 
think that our results may contribute to understanding 
whether schizophrenia shows any differences in neuronal 
and glial pathologies between the first episode and 
chronic patients, as well as knowledge about the possible 
degenerative or progressive nature of the disorder.
2. Materials and methods
In the present study, 30 CSPs and 24 FEPs were included. 
Inclusion criteria were age between 18 and 60 years old; 
fulfillment of DSM-IV diagnostic criteria for schizophrenia 
for CSPs; Clinical Global Impression score of moderate 
or above; illness history of longer than 3 years; and 
presence of one or more signs of delusion, hallucination, 
disorganized speech, disorganized or catatonic behavior 
symptoms, and short-term use of antipsychotic treatment 
(maximum 4 weeks) for FEPs. Exclusion criteria were the 
presence of mental retardation, neurological or organic 
mental disorders, and substance abuse history other than 
nicotine. The FEPs were followed for approximately 1 year 
to confirm the diagnosis. One patient who was diagnosed 
with the first episode was later diagnosed with neurological 
(Fahr) disease and excluded. Three patients were excluded 
because of bipolar mood disorder with psychotic features, 
and one patient was excluded because the MRS spectra 
values were inappropriate. Consequently, the FEP 
consisted of 19 patients. The control group was composed 
of 30 healthy volunteer subjects who were age- and sex-
matched, between 18 and 60 years of age, and working at 
the hospital. Axis I diagnoses were evaluated by using a 
semistructured psychiatric form (SCID-I) (32). For the 
control group, exclusion criteria were defined as fulfillment 
of diagnostic criteria for any psychiatric disorder, presence 
of neurological or organic mental disorder, and mental 
retardation. Patients and their relatives were informed 
about the objective and procedures of the study, and 
written informed consent was obtained either from the 
patient or their relatives. After obtaining the informed 
consent, patients and control subjects were included in 
the study. The research project was approved by the Local 
Ethics Committee of the Medical School of Pamukkale 
University, and the study was supported by the Scientific 
Research Projects Commission of the Medical Faculty of 
Pamukkale University (Project Number 2011TPF004). 
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Severity of symptoms was evaluated in the patient 
group by using the Scale for Assessment of Negative 
Symptoms (SANS) (33), Scale for Assessment of Positive 
Symptoms (SAPS) (34), and Clinic Global Impression 
Severity Scale (CGI) (35). 
2.1. Medication status 
Among the FEPs, 18 were receiving atypical antipsychotic 
agents (12 olanzapine, 4 risperidone, 2 aripiprazole) and 1 
patient was drug-free. 
Among the CSPs, 15 patients were receiving atypical 
antipsychotics (5 aripiprazole, 3 olanzapine, 3 paliperidone, 
2 risperidone, 2 ziprasidone), 9 patients were receiving dual 
atypical antipsychotics, 1 patient was receiving a typical 
antipsychotic (flupentixol), and 5 patients were receiving 
atypical and typical depot antipsychotic combinations. In 
the CSP group, 2 patients were receiving sodium valproate 
in addition to their ongoing antipsychotic treatment.
2.2. Proton magnetic resonance spectroscopy procedure
Proton MRS (1H-MRS) examinations were performed 
using a 1.5-T magnetic resonance device (GE Medical 
System, Milwaukee, WI, USA) with a standard head coil. 
First, a complete brain guiding image was taken at the 
sagittal plane to define consecutive sequence positions 
and for orientation. Sequentially, the magnetic resonance 
protocol was completed in the coronal plane at 10 mm 
of thickness by taking the T2 weighted fast spin echo 
sequence using time of repetition/time of echo (TR/TE): 
3000/85, field of view: 14, matrix: 352 × 352, and number 
of excitations: 1. MRS was performed by a single voxel 
(1H-voxel) technique implemented in the right prefrontal 
cortex, ACC, left thalamus, and left hippocampus areas 
(Figure 1). To define the voxel position and to minimize 
differences of implementation between subjects, a standard 
approach was used by using identifiable anatomical 
landmarks on a reference human brain atlas (36). The 
examined volume amount (volume of interest, VOI) was 
defined as 20 × 20 × 20 mm3 for each voxel, and it was 
implemented so that the related brain tissue in the frontal 
lobe was definitely covered. The chemical shift selective 
pulse (37) method was used to suppress water origin 
signals. Consequently, the point-resolved spectroscopy 
technique (38), which localizes spectroscopy volume, was 
used (TR/TE: 3000/35). Finally, short-time TE spectrums 
were obtained from the VOIs in the examined areas. For 
the quality control of spectroscopy, spectroscopy was 
regularly performed on the spectroscopy phantom, which 
was present in the device and had all metabolites, and 
quality control of the device was performed by observing 
the obtained spectrum quality. Additionally, standard 
signal-to-noise ratios (defined as the noise standard 
deviation ratio of NAA value), which were obtained 
from the obtained patient resonances and the software 
program existing in the device, were recorded, and spectra 
values below 3 were excluded from the measurements. 
Moreover, studies at 6 Hz, which was the full width at half 
maximum of water spectrum, measured during sending 
the spectroscopy sequence by the device or lower than 6 
Hz were included in the measurements. Obtained data 
were evaluated by the General Electric software spectral 
analysis program (Figure 2) Investigating levels of NAA-
, Cho-, and Cre-containing compounds in the DLPFC, 
ACC, thalamus, and hippocampus areas, NAA/Cre and 
Cho/Cre levels were calculated. The results were analyzed 
by a radiology specialist.
2.3. Statistical analysis
Statistical analysis was performed using SPSS 15.0. 
Intergroup differences in categorical variables were 
analyzed by chi-square test. Intergroup differences in 
continuous variables were analyzed by one-way analysis 
of variance (age, education level) when comparing three 
groups, and differences in two groups (i.e. clinical rating 
scores of FEPs and CSPs) were analyzed by Student t-test. 
In order to investigate whether MRS metabolite values 
and metabolite ratios differed between the groups we 
used multivariate analysis of covariance (MANCOVA) 
analysis. In these analyses neurometabolite levels or 
ratios for each examined area were defined as dependent 
variables, groups as between-subject factors, and age and 
sex as covariate. We used the Bonferroni test for post 
hoc pairwise comparisons. Correlations between disease 
Figure 1. H1-MRS application implemented in the DLPFC, ACC, thalamus, and hippocampus areas by using a 
single voxel technique.
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onset age, disease durations and clinical scale points, and 
metabolite levels or ratios showing intergroup differences 
were examined by performing Pearson correlation analysis.
3. Results  
There was no statistically significant difference in age, sex, 
or education level between the groups. For clinical scales, 
there was no statistically significant difference in SANS 
and CGI scores between the groups, but SAPS scores were 
significantly higher in the FEPs when compared with the 
CSPs (Table 1). The mean duration of the illness was 69.94 
± 90.18 days for FEPs and 10.60 ± 6.99 years for CSPs. 
There was no statistically significant difference between 
the mean ages of female (23.42 ± 7.86) and male (24.11 ± 
11.22) CSPs, while the mean age of females (33.90 ± 10.65) 
was significantly higher than that of male patients (24.22 ± 
6.18) among FEPs (P = 0.029).
3.1. DLPFC metabolite levels and metabolite ratios 
In MANCOVA analysis, a significant difference was 
determined in neurometabolites and neurometabolite 
ratios in the DLPFC between the groups (respectively 
Wilks’s lambda = 0.672, F = 2.588, P = 0.013; Wilks’s lambda 
= 0.616, F = 3.285, P = 0.002). There were significant 
differences in DLPFC Cho level and DLPFC NAA/Cho 
ratio between the groups (Table 2). DLPFC Cho levels 
were higher in CSPs than healthy controls (95% CI for 
difference, lower bound = 1.177; upper bound = 12.752, P 
= 0.011). The NAA/Cho ratio was lower in both the FEPs 
and CSPs than the healthy controls (respectively 95% CI for 
difference, lower bound = –0.558, upper bound = –0.193, P 
= 0.000 and lower bound = –0.472, upper bound = –0.056, 
P = 0.008). There was a decreasing but insignificant trend 
in the NAA/Cre ratio in CSP when compared with the 
controls, whereas there was an increasing trend in Cho/
Cre ratio (P = 0.078 and P = 0.079, respectively). There was 
no significant effect of age or sex on DLPFC metabolite 
levels or ratios.
3.2. Hippocampus metabolite levels and metabolite 
ratios 
Hippocampal 1H-MRS metabolite levels were obtained 
in 14 FEPs, 22 CSPs, and 26 controls. Hippocampal NAA 
levels were significantly different between the groups 
(Wilks’s lambda = 0.793, F = 3.138, P = 0.018). In post hoc 
pairwise analysis, it was determined that NAA levels in 
CSPs were significantly lower than in the control group (P 
= 0.003) (95% CI lower bound = –18.689, upper bound 
= –4.915). Hippocampal metabolite levels or ratios in the 
FEPs were not different from the control group. There was 
no significant age or sex effect on hippocampus metabolite 
levels or ratios. There was no significant difference in 
neurometabolite levels and ratios in the ACC and thalamus 
between the groups.
3.3. Correlations between neurometabolite levels and 
clinical variables 
In the FEP group DLPFC NAA/Cho ratio and SANS scores 
were negatively correlated (r = –0.462, P = 0.050). In the 
CSP group, SANS scores were positively correlated with 
DLPFC Cho levels (r = 0.376, P = 0.044) and negatively 
correlated with DLPFC NAA/Cho ratio (r = –0.455, P 
= 0.013). Additionally, there was a significant negative 
Figure 2. Graphic presentation of metabolite levels and the obtained peak values in the areas by the H1-MRS study.
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correlation between NAA/Cho ratio and age at onset in 
CSPs (r = –0.416, P = 0.025).
4. Discussion
In the present study, brain metabolite levels of FEPs and 
CSPs were compared with those of healthy controls. The 
main findings were lower NAA/Cho ratios and higher Cho 
levels in the DLPFC and lower hippocampal NAA levels in 
the CSPs compared to the healthy controls. In the FEP group, 
the DLPFC NAA/Cho ratio was lower than in the control 
group. The DLPFC NAA/Cho ratio showed a significant 
correlation with negative symptom severity in both the FEPs 
and CSPs. 
In studies with participants similar to ours, such as those 
with approximately equal female/male ratio and patients 
receiving short-term antipsychotic treatment, it was reported 
that NAA/Cre ratios in the prefrontal cortex, thalamus, 
temporal lobe, and hippocampus in FEPs were not different 
from those of healthy individuals (17,39–42). On the 
other hand, similar to our results, Bertolino et al. reported 
that NAA/Cho and NAA/Cre ratios were decreased in the 
DLPFC and hippocampus in patients with schizophreniform 
disorder (13). Jessen et al. reported that NAA/Cho ratio was 
decreased in the frontal lobe in FEPs, and low NAA/Cho ratio 
and high Cho/Cre ratio in the ACC were related to switching 
to chronic schizophrenia (43). It was also reported that CSPs 
had lower NAA/Cho levels than healthy individuals, and it 
was proposed that the decrease in NAA/Cho ratio reflected 
the presence of neuronal loss (9,44). 
The Cho peak is a complex formed by mainly phosphoryl 
choline and glycerophosphoryl choline. The Cho peak is 
elevated in tumors and inflammatory or neurodegenerative 
processes (45,46). It was reported that Cho levels in the 
frontal lobe were not generally changed or increased in CSPs 
(29,30,47). High Cho concentrations may reflect decreased 
glucose metabolism or abnormalities in the phospholipid 
membrane formation (30,31,47–49).
The issue that must be discussed here is that decrease 
in DLPFC NAA/Cho levels may be a secondary condition 
emerging in association with Cho increase in this region. 
Although Cho levels in the FEPs were not different from 
healthy individuals, decrease in NAA/Cho ratio and 
similarity of DLPFC Cho/Cre ratios between patient and 
control groups indicate that this condition may not be a 
secondary sign only, but it may be related to the possible 
change in the NAA level. Some studies that compared CSPs 
and FEPs with healthy individuals reported that there were 
significant decreases in DLPFC NAA or NAA/Cre ratios 
in both patient groups (7,8,27). In the present study, no 
significant difference was observed in DLPFC NAA or NAA/
Cre ratios between CSPs and the healthy control group. 
Follow-up studies have reported that NAA levels were not 
low at the baseline; the decrease occurred within the first 
year after the symptoms had started (7,10,50). The onset of 
symptoms among our FEPs was approximately 70 days; this 
might cause the lack of difference in NAA levels between the 
patients and healthy individuals. 
Moreover, atypical antipsychotic treatment may have 
acted as a confounding factor for DLPFC NAA levels. 
Cross-sectional and longitudinal studies have proposed 
that atypical antipsychotics normalized the decreased NAA 
levels (10,13,24). It has been reported that NAA levels 
selectively increased in the DLPFC within 4 weeks but not 
in the temporal lobe (13). In our study, the FEPs included 
patients receiving minimal antipsychotic treatment (up to 4 
weeks), whereas CSPs were being treated mainly by atypical 
antipsychotics. This condition might prevent us from 
determining NAA changes. 
With significant decrease in the DLPFC NAA/Cho 
ratio in both patient groups compared to healthy controls 
Table 1. Sociodemographic and clinical characteristics of diagnostic groups.
First episode psychosis Chronic schizophrenia Control    
Number % Number % Number % Test statistics P
Sex
Female 10 52.6 12 40.0 14 46.7 c2 = 0.772 0.68
Male 9 47.4 18 60.0 16 53.3
Mean SD Mean SD Mean SD P
Age 29.32 9,92 34.33 11.19 30.93 6.58 F = 1.897 0.157
Education duration 10.50 3.63 8.56 3.19 11.23 3.37 F = 4.75                  0.073
SANS 31.63 20.36 27.13 14.21 t = 0.911 0.367
SAPS 29.11 15.14 19.33 9.65 t = 2.508 0.018
CGI 4.84 0.95 4.46 0.72     t = 1.687 0.073
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and significant increase in DLPFC Cho levels in chronic 
patients, DLPFC neuronal integrity might be impaired at 
the onset of schizophrenia. NAA changes might not be 
detected during treatment, but impaired neuronal density 
or disturbed energy metabolism might persist starting from 
the first episode to the chronic stages. In the present study, 
the DLPFC NAA/Cho ratio was significantly correlated 
with negative symptom severity in both FEPs and CSPs. 
We also found that DLPFC Cho levels in chronic patients 
were significantly correlated with negative symptoms and 
age at onset. In previous studies, a negative correlation was 
also reported between PFC NAA/Cre ratio and negative 
symptoms, which supports the association of the frontal 
cortex with negative symptoms in schizophrenia (12,51). 
Starting with Nasrallah et al.’s study, a decreased 
hippocampal NAA level was supported by several other 
studies in schizophrenia patients, and it was reported that 
NAA decrease in the hippocampus was approximately 
22% (52). Considering that the decrease in hippocampal 
NAA levels is a more consistent result when compared to 
those in other brain areas such as the frontal cortex, basal 
ganglion, thalamus, and cingulate cortex in CSPs, it may 
be interpreted as strong evidence for neuronal/axonal loss 
in the hippocampus in schizophrenia (14,16,20,53–55). 
In our study, similar to these results, NAA levels in the 
hippocampus were significantly decreased in the CSPs 
when compared to healthy controls. Consistent with 
previous reports, this finding was not found in the FEP 
group, so it suggests a progressive process in schizophrenia 
(14–16,48). 
It was observed that there was no difference in ACC 
metabolite levels between CSPs, FEPs, and healthy 
controls in the majority of studies (20–22,25). The 
common characteristic of studies reporting decreases in 
ACC NAA levels is that they were performed on chronic 
patients under typical antipsychotic treatment (23–25). In 
a recent and comprehensive review, it was reported that 
when looking at the methodologically rigorous studies, 
no NAA, Cho, Cre, or myo-I alterations could be found 
in schizophrenia patients (49,56). Consistent with the 
literature, there was no difference in NAA levels in the 
ACC in CSPs and FEPs when compared with the healthy 
individuals in the present study.
It was reported that there was neuronal loss, decreased 
volume, and synaptic degeneration in the thalamus 
of schizophrenia patients consistently with thalamic 
dysfunction in schizophrenia pathogenesis (57–60). When 
MRS studies on FEPs were evaluated, similar to our results, 
NAA, NAA/Cho, Cho/Cre, and NAA/Cre values in the 
thalamus were not different from those of healthy controls 
Table 2. Metabolite levels and metabolite ratios in the DLPFC and hippocampus.
  First episode (n = 19)
Chronic sch
(n = 30)
Controls 
(n = 30) Post hoc comparisons
 DLPFC Mean SD Mean SD Mean SD F     P
NAA 60.36 12.55 61.10 12.2 62.40 10.20 0.462 0.561
Cre 38.55 6.61 39.33 8.17 36.96 5.93 0.946 0.382
Cho 39.26 9.15 40.39 8.91 34.81 5.82 4.956 0.011      CSP > C
Myo-I 29.07 5.02 29.30 5.24 27.55 4.92 0.645 0.528
NAA/Cre 1.61 0.25 1.58 0.30 1.72 0.23 2.689 0.078
NAA/Cho 1.60 0.21 1.57 0.27 1.84 0.28 13.618 0.000     CSP, FE < C
Cho/Cre 1.02 0.19 1.03 0.20 0.94 0.14 2.675 0.079
Myo/Cre 0.71 0.11 0.75 0.20 0.72 0.16 0.164 0.849
Hippocampus (n = 14) (n = 22) (n = 26)
NAA 54.64 14.29 45.73 11.06 56.85 12.09 6.612 0.003      CSP < C      
Cre 37.21 9.69 32.86 6.32 38.38 7.07 2.262 1.113          
Cho 37.50 10.79 31.04 7.42 37.86 8.39 3.077 0.055           
Myo-I 29.91 6.06 28.56 3.16 28.65 3.77 1.090 0.342
NAA/Cre 1.53 0.25 1.42 0.18 1.50 0.16 1.956 0.149
NAA/Cho 1.56 0.37 1.44 0.26 1.60 0.27 0.276 0.760
Cho/Cre 1.03 0.23 0.97 0.17 0.95 0.17 0.288 0.751
Myo-I/Cre 0.84 0.13 0.88 0.20 0.75 0.16 0.590 0.559    
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in schizophreniform cases or FEPs (18,61). It was also 
reported that Cho, Cre, and myo-I levels in the thalamus 
were not different in the FEPs from healthy controls (39). 
In the present study, thalamic metabolites in CSPs 
were not different from those of healthy controls. Results 
of studies examining thalamic metabolite levels in CSPs 
are divergent. While there was no significant difference 
in metabolite levels and ratios when compared with the 
control cases (20,21,62–64), decreases in NAA and NAA/
Cre ratios were reported in some studies. It was determined 
that thalamic NAA, Cre, and Cho levels were decreased 
in male patients, children and adolescent patients with 
schizophrenia, and individuals who had high genetic 
risk for schizophrenia (4,28,65). Additionally, it has been 
reported that decreased NAA or NAA/Cho levels were 
associated with acute psychotic attack, active auditory 
hallucinations, and typical antipsychotic use in the CSP 
group (66–69). Considering these findings, our patient 
characteristics and atypical antipsychotic treatment might 
have affected our results.
When the limitations of our study are considered, 
our sample size is quite similar to the previous H1-MRS 
studies. However, a metaanalysis evaluating MRS findings 
considered that 39 patients and 39 controls are required 
for acceptable statistical power, and so our sample size may 
be accepted as relatively limited (3,70). The present study 
was performed by using a 1.5-T MRS device with a short 
TE. The single voxel MRS procedure used in the present 
study is methodologically comparable with many previous 
studies performed with this field strength. However, it 
was reported that MRS techniques with higher magnetic 
field strength and high resolution power would facilitate 
signal perception and thus increase the sensitivity (49,56). 
In addition, we did not evaluate glutamate and glutamine 
levels, which might be differentiated in spectra using 
MRS protocols with higher magnetic field strength. As 
previously reported, not excluding the drug effects on brain 
metabolites is another limitation of our study (13,71–74). 
 The advantages of our study are that the sexes were 
represented at a nearly equal ratio among both the FEPs and 
CSPs, the diagnoses of FEPs were confirmed by follow-up, 
patient groups were composed of age-matched individuals, 
and age and sex effects on MRS metabolites were controlled 
in the statistical analyses. Moreover, we included absolute 
metabolite values or ratios of the investigated brain area 
in MANCOVA and analyzed the intergroup metabolite 
differences by using a multivariable covariant analysis to 
decrease the possible type II error. Therefore, we think 
that our results are reliable for controlling the confounding 
factors in statistical analysis. The present study is also one 
of studies comparing FEPs and CSPs with healthy controls 
in the same study design and evaluating the DLPFC, ACC, 
thalamus, and hippocampus, which are thought to be 
involved in schizophrenia etiology at the same time. 
In conclusion, our results showing higher Cho levels 
and lower NAA/Cho ratios in the DLPFC as well as lower 
NAA levels in the hippocampus in CSPs when compared 
with the healthy controls are consistent with the impaired 
neuronal integrity and membrane phospholipids reported 
in the advanced stages of the disease by previous studies 
(19). Decreased NAA/Cho ratio in FEPs when compared 
to the healthy controls supports the role of DLPFC 
dysfunction in schizophrenia development and also 
suggests existent neuronal dysfunction starting at the 
onset of disease. Further longitudinal studies with larger 
sample sizes with FEPs followed for longer periods of time, 
with better control on the drug effects, and with higher 
resolutions of MRS technique are required.
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